化学科研者一站式服务平台


  • (3S)-6-[[2',6'-二甲基-4'-[3-(甲磺酰基)丙氧基][1,1'-联苯]-3-基]甲氧基]-2,3-二氢-3-苯并呋喃乙酸

    2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid

化合物简介

TAK-876 is a selective G protein-coupled receptor 40 (GPR40) agonist. TAK-876 is a novel oral medication that has been developed to improve the secretion of insulin in a glucose-dependent manner, which has the potential to improve the control of blood sugar levels without the risk of hypoglycemia.

基本信息

CAS:1000413-72-8
中文别名
英文别名:Fasiglifam (INN);Fasiglifam;3-Benzofuranacetic acid,6-[[2\',6\'-diMethyl-4\'-[3-(Methylsulfonyl)propoxy][1,1\'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-,(3S);TAK-875;((3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic acid;
分子式:C29H32O7S
分子量:524.625
精确质量:524.187
Psa:107.51
Logp:6.3944

编号系统

MDL号:MFCD18251445

物化性质

密度:1.3±0.1g/cm3
沸点:739.1±60.0°Cat760mmHg
闪点:400.8±32.9°C
蒸汽压:0.0±2.6mmHgat25°C
折射率:1.587
储存条件:2-8℃

安全信息

生产方法及用途

合成路线

上游原料

下游产品

图谱

1H NMR : Predict


13C NMR : Predict


加载中...